Coagulant Therapeutics

What Coagulant Therapeutics does

Coagulant Therapeutics Corporation is a privately held, pre-clinical-stage biologics company founded in 2019 and headquartered in Berkeley, California. The company develops engineered recombinant protein therapeutics for acute bleeding — a category that includes severe postpartum hemorrhage, intracranial hemorrhage, traumatic brain injury, and trauma-induced coagulopathy — an indication space with no FDA- or EMA-approved systemic hemostatic pharmaceutical agent. The company was founded by Terry Hermiston, former Site Head and VP of Biologics Research US at Bayer HealthCare, and acquired FVIIa assets and over 30 patents from Bayer AG at inception; these assets originated from Maxygen and represent a $120 million prior R&D investment.

The core product candidate is CT-001, an engineered recombinant Factor VIIa (rFVIIa) with dual modifications: desialylation that yields a circulating half-life of approximately three minutes versus roughly two hours for wild-type rFVIIa (reducing systemic thromboembolic risk), and Gla-domain engineering providing 2-5x greater hemostatic potency. The platform is supported by two proprietary Activated Protein C (APC) antibody libraries — a llama-derived nanobody library and a directed evolution antibody library — yielding lead candidate CT-003 for trauma-induced coagulopathy. Preclinical efficacy has been demonstrated in murine acute bleeding models, coagulopathy models, and ex vivo peripartum patient blood samples, with peer-reviewed publications in Blood Advances, Journal of Trauma and Acute Care Surgery, Thrombosis Research, and Research and Practice in Thrombosis and Haemostasis. CT-001 received FDA Orphan Drug Designation for postpartum hemorrhage in 2022 and is being prepared for a Phase 1 clinical trial.

The company is pre-revenue and operates as an enterprise-focused pharmaceutical developer targeting hospital and emergency care settings through direct sales upon regulatory approval. It has raised approximately $36 million in a 2022 Series A from a South Korean investor consortium (Korea Omega Investment Corp., Deutsche Telekom Capital Partners, Hana WM Center) to fund CT-001 Phase 1 development, with active research collaborations with The Scripps Research Institute, Duke University, and Pusan National University. The intended geographic footprint spans the United States, EU5, and Japan, with a stated $18 billion annual market opportunity.

Name

Coagulant Therapeutics

Legal name

Coagulant Therapeutics Corporation

Website

https://coagulanttherapeutics.com

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

1–10 employees

Ownership category

akta.pro rank

Product category

Hemostatic Biopharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Blood Factors & Hemostasis Biologics (recombinant clotting factors, thrombolytics) (HLAAAAAL)

akta.pro secondary industries

Plasma-Derived Therapeutics (immunoglobulins, albumin, clotting factors) (HLAAAAAI), Plasma-Derived Coagulation Factors (Hemophilia Therapies) (HLAIAHAB)

Keywords

• Acute bleeding therapeutics
• Recombinant factor VIIa
• Hemostatic drug development
• Postpartum hemorrhage treatment
• Coagulation cascade biologics

Headquarters

HQ city

San Francisco

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Pharmaceutical Drug Development & Commercialization: Pre-revenue biotech company developing therapeutics for acute bleeding. Revenue will come from commercialization of CT-001 and pipeline candidates upon regulatory approval. Target market estimated at $18 billion annually with no approved competing pharmaceutical therapies.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

Coagulant Therapeutics is a pre-clinical biopharmaceutical company developing engineered recombinant Factor VIIa (CT-001) and Activated Protein C (APC) antibody therapeutics to treat acute bleeding, including severe postpartum hemorrhage, intracranial hemorrhage, traumatic brain injury, and trauma. The lead candidate CT-001 combines rapid clearance (3-minute half-life) with 2-5x greater potency than wild-type rFVIIa to address the unmet need for safe, FDA-approved systemic hemostatic agents.

Product overview

Coagulant Therapeutics is a biologics platform company developing a portfolio of therapeutics targeting the coagulation cascade to treat acute bleeding. The core product is CT-001, a novel engineered Factor VIIa with rapid clearance and enhanced potency for treating severe postpartum hemorrhage, trauma, traumatic brain injury, and intracranial hemorrhage. Supporting the platform are two APC (Activated Protein C) antibody programs: a proprietary llama nanobody library and a directed evolution antibody library. CT-003 is the lead APC antibody candidate for trauma-induced coagulopathy. The company is advancing these assets toward clinical development with CT-001 targeting Phase 1 trials in severe postpartum hemorrhage.

Differentiator

Problem solved

Functional benefit

Products and services

• CT-001 A next-generation recombinant Factor VIIa engineered for rapid clearance (~3 minute half-life vs ~2 hours for wild-type rFVIIa) and enhanced Gla domain engineering providing 2-5x greater potency. Lead candidate for treating acute bleeding including severe postpartum hemorrhage, trauma, traumatic brain injury, and intracranial hemorrhage. FDA Orphan Drug Designation granted in 2022.
• CT-003 Lead candidate from the APC antibody program that ameliorates endotheliopathy by preventing vascular endothelial cell layer permeability and shifts PAR1 signaling towards anti-inflammation and cytoprotection. Being developed for treatment of trauma-induced coagulopathy and hemophilia.
• CT-005 APC antibody program candidate identified from the directed evolution antibody library targeting non-active site epitopes of Activated Protein C. Under evaluation as an alternative Phase 1 candidate alongside CT-003.

Quantifiable outcome

• 20-40% of hemorrhage-related deaths potentially preventable with rapid hemostatic control
• +3 more outcomes

Named customers3 records

Segments6 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Five partnerships are on record, tiered core and secondary.

• The Scripps Research InstitutecoreStrategic or Co-development Partner · 27 February 2023Collaboration with Dr. Laurent Mosnier, Professor in the Department of Translational Medicine at Scripps, investigating APC-targeted antibodies that selectively modulate anticoagulant and anti-inflammatory activities. Led to publication in Blood Advances (2023 and 2025) describing nanobody library and directed evolution approaches for APC modulation.
• Duke UniversitycoreStrategic or Co-development Partner · 13 February 2023Collaboration with Dr. Andra James, Professor Emeritus of Obstetrics and Gynecology at Duke University, on ex vivo studies of CT-001 activity in peripartum patient blood samples. Duke served as senior research institution for postpartum hemorrhage studies published in Blood Advances (2024).
• Pusan National University School of MedicinesecondaryStrategic or Co-development Partner · 13 February 2023Collaboration with Dr. Seung-Chul Kim at Pusan National University School of Medicine, Busan, Republic of Korea, on studies of CT-001 activity in peripartum patient blood samples, published alongside Duke University findings.
• Creative Destruction Lab (CDL)secondaryStrategic or Co-development Partner · 1 January 2023Accepted into the Advanced Therapies Stream of CDL program, a nonprofit delivering objectives-based mentorship for seed-stage science companies. Provides access to top industry mentors to advance pipeline assets toward clinical development.
• Bayer AGcoreOEM/ Whitelabel/ Licensing Partner · 1 January 2019Licensing agreement providing access to Bayer FVIIa assets and intellectual property originally developed at Bayer's Berkeley facility and engineered by Dr. Hermiston's team. Assets include all FVIIa technology and related patents (over 30) from Bayer's hemophilia program, which was itself acquired by Bayer from Maxygen for $120 million.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Grifols: Major plasma-derived therapeutics manufacturer including coagulation factor products (e.g., AlphaNine, Koāte) and the Bio Supplies division. Directly adjacent biologics manufacturing, hospital-channel sales force, and product portfolio relevant to CT-001's commercial buildout.
• Takeda Pharmaceutical: Through the Shire acquisition, Takeda owns the Advate/Adynovate/Recombinate hemophilia franchise and is a global hemostasis leader. Operates across coagulation and hematology indications comparable to Coagulant's target patient populations, with deep hospital and specialty distribution.
• Alexion / AstraZeneca Rare Disease: Owns the C1-esterase inhibitor franchise (Haegarda, Cinryze) for hereditary angioedema and rare hematologic complement/coagulation assets. Comparable rare/orphan drug commercialization playbook in the acute hospital setting relevant to CT-001's orphan-designated PPH program.
• Bayer AG: Original developer and licensor of Coagulant's FVIIa asset portfolio (Bayer HealthCare / Maxygen heritage). Bayer retains a broader hemostasis portfolio (Kovaltry, Jivi) and pharmaceutical R&D scale that dwarf the Coagulant platform; relevant as both licensor and potential strategic acquirer.
• CSL Behring: Leading global plasma-derived coagulation factor producer (e.g., Hemophilia therapies, Idelvion, Afstyla, Kcentra for urgent warfarin reversal). Provides commercial and clinical benchmarks for hospital-channel hemostatic product launches and indication expansion strategies.
• Octapharma: Privately-held plasma-derived therapy company with factor products (e.g., Nuwiq, Wilate) serving hemophilia and trauma-related bleeding markets. Comparable vertically-integrated plasma/biologics model relevant to Coagulant's manufacturing and commercialization pathway.

Direct peers

• Novo Nordisk: Markets NovoSeven (recombinant Factor VIIa), the off-label standard-of-care that CT-001 is engineered to improve upon for acute bleeding. Same mechanism class (rFVIIa), same target indications (PPH, trauma, ICH), directly comparable benchmark for both clinical positioning and commercial displacement.

Emerging players

• ApcinteX: Early-stage biotech developing a humanized monoclonal antibody (AAV8-mediated APC inhibitor targeting EPCR) for hemophilia — directly comparable APC-pathway therapeutic approach with similar target indications, useful commercial/clinical comparator for Coagulant's APC nanobody franchise.
• Pharming Group: Specialized rare-disease biotech with Ruconest (C1-INH replacement) for hereditary angioedema — analogous orphan-designated plasma-protein biologic commercialized through hospital specialty channels. Provides commercial and reimbursement benchmarks for Coagulant's hospital-deployed hemostatic portfolio strategy.
• BioMarin Pharmaceutical: Pursued Roctavian (valoctocogene roxaparvovec) gene therapy for hemophilia A — a competing modality to factor-replacement therapeutics. Signals the broader competitive landscape in hemostasis and acute bleeding, including durable alternatives that could erode rFVIIa-class commercial opportunity.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/coagulant-therapeutics-inc

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Coagulant Therapeutics